162 active not recruiting. 162 Phase 2, 21 Phase 3, 20 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 162 | Active not recruiting 162 |
| Phase 3 | 21 | Active not recruiting 21 |
| Phase 1 | 20 | Active not recruiting 20 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD Psilocybin - Post Traumatic Stress Disorder, PTSD | Phase 2 | Active not recruiting | Unity Health Toronto | 15 | 2026-06-01 | 2026-10-06 |
| Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies Psychotherapy, Psilocybin, Survey Administration - Anxiety, Depression | Phase 2 | Active not recruiting | University of Washington | 16 | 2026-05-19 | 2026-10-29 |
| A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression Treatment with Ketamine Hydrochloride Prolonged-Release Tablets - Major Depressive Disorder (MDD) | Phase 2 | Active not recruiting | Daniel Lindqvist | 12 | 2026-03-13 | 2026-06-18 |
| Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms OTX-601 Digital Therapeutic, OTX-003 Comparator app - PTSD, Post Traumatic Stress Disorder | Phase 2 | Active not recruiting | Oui Therapeutics, Inc. | 40 | 2025-12-09 | 2026-07-15 |
| Oral and Topical Phytocannabinoids for Psoriasis Oral Cannabis Extract, Topical cannabis cream - Psoriasis Vulgaris | Phase 2 | Active not recruiting | Federal University of Latin American Integration | 37 | 2025-11-01 | 2026-09-24 |
| Extended-release Buprenorphine as a Novel Low-dose Induction Strategy Extended-release Buprenorphine - Opioid Use Disorder | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 8 | 2025-10-27 | 2026-07-09 |
| Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) NPI-001, Placebo - Alzheimer´s Disease | Phase 2 | Active not recruiting | Arctic Therapeutics | 33 | 2025-10-14 | 2026-08-03 |
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia Neflamapimod, Placebo - Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Active not recruiting | EIP Pharma Inc | 20 | 2025-10-02 | 2026-07-06 |
| Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type 12 cm2 - 2 Active DMTS Patches, 6 cm2 - 1 Active and 1 Placebo DMTS Patches, Placebo - 2 Placebo DMTS Patches - Agitation | Phase 2 | Active not recruiting | Teikoku Pharma USA, Inc. | 150 | 2025-09-16 | 2026-10-27 |
| A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease VHB937, Placebo - Alzheimer's Disease | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 97 | 2025-08-07 | 2026-10-21 |
| Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 Varenicline - Alcohol Use Disorder, Hiv | Phase 2 | Active not recruiting | Yale University | 30 | 2025-06-16 | 2026-04-16 |
| Novel and Conventional Interventions for Cognitive and Emotional Flexibility in Patient Trauma D-Cycloserine (DCS), Transcranial Magnetic Stimulation, Unified Protocol - Depression, Anxiety | Phase 2 | Active not recruiting | Mclean Hospital | 75 | 2025-06-01 | 2026-10-09 |
| PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) Psilocybin 25 mg, Maltodextrin (Placebo) - Alcohol Use Disorder (AUD), PTSD | Phase 2 | Active not recruiting | Nathan Brashares Sackett | 40 | 2025-06-01 | 2026-08-13 |
| Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease SKY-0515, SKY-0515 Placebo - Huntington Disease, Huntingtons Disease | Phase 2 / Phase 3 | Active not recruiting | Skyhawk Therapeutics, Inc. | 120 | 2025-05-27 | 2026-05-01 |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia ALKS 2680, Placebo - Idiopathic Hypersomnia | Phase 2 | Active not recruiting | Alkermes, Inc. | 126 | 2025-05-22 | 2026-09-25 |
| Multi-session Transcranial Alternating Current Stimulation to Improve Dual-task Standing and Brain Activity in Older Adults With Mild Cognitive Impairment real tACS, sham tACS - Mild Cognitive Impairment (MCI) | Phase 2 | Active not recruiting | High Point University | 20 | 2025-05-13 | 2026-09-16 |
| Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults AGB101, Placebo - Hippocampal Overactivity, Dementia | Phase 2 | Active not recruiting | Johns Hopkins University | 60 | 2025-04-17 | 2026-08-31 |
| Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase Cannabis 50 mg of CBD and 5 mg of THC - Alzheimer Disease (AD) | Phase 1 / Phase 2 | Active not recruiting | Federal University of Latin American Integration | 61 | 2025-04-07 | 2025-08-12 |
| Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression/Anxiety Third wave VR therapy - Depression Anxiety Disorder | Phase 2 | Active not recruiting | Orygen | 75 | 2025-04-01 | 2026-09-14 |
| Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults ABX-002 - Bipolar Disorder Depression | Phase 2 | Active not recruiting | Autobahn Therapeutics, Inc. | 35 | 2025-03-28 | 2026-05-26 |
Showing 20 of 162. Sign in to see all of them.
Alzheimer Disease (29) · Cognitive Dysfunction (23) · Depression (18) · Dementia (16) · Depressive Disorder, Major (14) · Alcoholism (12) · Anxiety Disorders (12) · Autism Spectrum Disorder (10) · Huntington Disease (8) · REM Sleep Behavior Disorder (7) · Opioid-Related Disorders (6) · Autistic Disorder (5) · Depressive Disorder, Treatment-Resistant (5) · Inflammation (5) · Neurodegenerative Diseases (5)
Nervous System Diseases (73) · Neurocognitive Disorders (61) · Central Nervous System Diseases (55) · Brain Diseases (54) · Neurodegenerative Diseases (44) · Pathological Conditions, Signs and Symptoms (38) · Dementia (33) · Cognition Disorders (29) · Tauopathies (29) · Behavior (28) · Chemically-Induced Disorders (28) · Substance-Related Disorders (27) · Signs and Symptoms (23) · Behavioral Symptoms (21)
Psilocybin (11) · Ketamine (5) · Cannabidiol (4) · Dasatinib (4) · Fecal Microbiota Transplantation (3) · Quercetin (3) · Sodium Chloride (3) · lecanemab (3) · nabiximols (3) · Carvedilol (2) · Clavulanic Acid (2) · Cognitive Behavioral Therapy (2) · Cycloserine (2) · Exercise (2) · Haloperidol (2)
M.D. Anderson Cancer Center (7) · Cedars-Sinai Medical Center (4) · Washington University School of Medicine (4) · Hoffmann-La Roche (3) · New York State Psychiatric Institute (3) · University of California, San Diego (3) · Yale University (3) · Arctic Therapeutics (2) · Arizona State University (2) · Brown University (2) · Columbia University (2) · Federal University of Latin American Integration (2) · Johns Hopkins University (2) · Massachusetts General Hospital (2) · Northwestern University (2)
United States (115) · United Kingdom (21) · Australia (19) · Canada (18) · Spain (17) · France (16) · Germany (10) · Italy (9) · Japan (8) · Poland (7) · Belgium (6) · Brazil (6) · Netherlands (6) · Sweden (6) · China (4)
David Hui (2) · James B Adams, PhD (2) · Michele Tagliati, MD, FAAN (2) · Randall J Bateman, MD (2) · Richard E Frye, MD, PhD (2) · Abdelraouf Elmohsen, Professor (1) · Achim Schneeberger, MD (1) · Ahmed Elshahid, Professor (1) · Akira Sekikawa, MD, PhD, PhD (1) · Alasdair Coles, PhD FRCP (1) · Amy Berger, MD (1) · Amy E Brown, MD (1) · Anelyssa D'Abreu, MD (1) · Anthony Back, MD (1)
PMID 34366147, PMID 36463457, PMID 38489195, PMID 10214756, PMID 10406987, PMID 10527042, PMID 10853813, PMID 10979878, PMID 11076832, PMID 11121838, PMID 11400186, PMID 11724917, PMID 12498954, PMID 12904089, PMID 15175402, PMID 15345186, PMID 15645531, PMID 15779234, PMID 16025231, PMID 16442563, PMID 16528082, PMID 16715205, PMID 16837857, PMID 17190953, PMID 18079166, PMID 18349024, PMID 19018276, PMID 20146689, PMID 20188504, PMID 20846908, PMID 20887968, PMID 20976736, PMID 21045744, PMID 21421334, PMID 21538520, PMID 21571570, PMID 21700495, PMID 21802993, PMID 22321865, PMID 22483040, PMID 22508280, PMID 23024438, PMID 23160999, PMID 23266935, PMID 23329524, PMID 23347909, PMID 23562390, PMID 23647842, PMID 23970363, PMID 24332912
2023 (8), 2018 (2), R01AG046179 (2), R01AG053267 (2), R56AG053267 (2), U01AG042791 (2), U01AG059798 (2), 2025 (1), P01AA029545 (1), R01AA029398 (1), R01AG051618 (1), R01AG058691 (1), R01AG061091 (1), R01AG061111 (1), R01AG062624 (1)